

this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

*Amendments*

*In the Claims:*

✓  
Please cancel claims 8-17 without prejudice or disclaimer.

✓  
Please substitute the following claim 1 for the pending claim 1:

B<sup>1</sup>

---

1. (Twice amended) A method of preventing damage to the excitable cells of a patient that express a transient potassium ( $K^+$ ) current which comprises administering to said patient during or after said patient undergoes or has undergone an ischemic event, an effective amount of an angiotensin-II receptor antagonist which increases a transient potassium ( $K^+$ ) current in said excitable cells of said patient.

---

Please substitute the following claim 18 for the pending claim 18:

---

18. (Once amended) The method of preventing damage to the excitable cells of a patient as claimed in claim 1, wherein said angiotensin-II receptor antagonist crosses the blood-brain barrier.

B<sup>2</sup>

{ Please substitute the following claim 19 for the pending claim 19: }

19. (Once amended) The method of preventing damage to the excitable cells of a patient as claimed in claim 1, wherein said angiotensin-II receptor antagonist is losartan.

{ Please substitute the following claim 20 for the pending claim 20: }

20. (Once amended) The method of preventing damage to the excitable cells of a patient as claimed in claim 1, wherein said angiotensin-II receptor antagonist is saralasin.

---